Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide
6 June 2008
Novo Nordisk today announced headline clinical results from a phase 3 clinical study (LEAD(TM) 6) comparing the effects of liraglutide, a once-daily human GLP-1 analogue, with exenatide, a twice-daily GLP-1 analogue. The 26-week study, which is the first study to provide a direct comparison between the two GLP-1 analogues, included 464 people with type 2 diabetes who were randomised to treatment with either liraglutide once daily or exenatide twice daily, as add-on to their existing treatment consisting of metformin, sulfonylurea, or a combination of both.
RSS Feed
The latest Novo Nordisk news are now available through Really Simple Syndication - RSS.
